Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of LB54640 in Hypothalamic Obesity
NCT06046443Phase 2Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Jul 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of LB54640 in hypothalamic obesity (HO), sponsored by Rhythm Pharmaceuticals. Started Jul 2024; status: completed.
02
Drugs
LB54640
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on NCT06046443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06046443.